Saracatinib is a quinazoline derivative substituted at positions 4, 5, and 7 with (5-chloro-2H-1,3-benzodioxol-4-yl)amino, (oxan-4-yl)oxy, and 2-(4-methylpiperazin-1-yl)ethoxy groups, respectively. It is a dual inhibitor of c-Src and Abl tyrosine kinases (IC50 = 2.7 and 30 nM). Originally developed by AstraZeneca for cancer treatment, it was granted orphan drug designation by the FDA in 2019 for idiopathic pulmonary fibrosis (IPF), a lung disease characterized by fibrosis. Saracatinib functions as an antineoplastic agent, a non-specific protein-tyrosine kinase inhibitor, a radiosensitizing agent, an autophagy and apoptosis inducer, and an anticoronaviral agent. It belongs to quinazolines, secondary amines, N-methylpiperazines, aromatic ethers, oxanes, benzodioxoles, organochlorine compounds, and diethers.
